The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 11, 2024
Filed:
May. 22, 2018
Applicant:
Novartis Ag, Basel, CH;
Inventors:
Jonathan Deane, San Diego, CA (US);
Yaiza Diaz-De-Durana, San Diego, CA (US);
Michael DiDonato, San Diego, CA (US);
Christophe Filippi, Studio City, CA (US);
Glen Spraggon, San Diego, CA (US);
Assignee:
NOVARTIS AG, Basel, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/55 (2006.01); A61K 38/20 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/08 (2006.01); C07K 16/10 (2006.01); C07K 19/00 (2006.01); C12N 5/071 (2010.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07K 16/1027 (2013.01); A61K 38/2013 (2013.01); A61K 39/3955 (2013.01); A61K 47/6801 (2017.08); A61P 35/00 (2018.01); C07K 14/55 (2013.01); C07K 19/00 (2013.01); C12N 5/0636 (2013.01); C12N 5/0682 (2013.01); A61K 2039/505 (2013.01); A61K 45/06 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/94 (2013.01); C07K 2319/30 (2013.01);
Abstract
The present disclosure provides for IL2 engrafted into the CDR sequences of an antibody having preferred therapeutic profiles over molecules known and used in the clinic. In particular, the provided antibody cytokine engrafted protein compositions increase or maintain CD8+ T effector cells while reducing the activity of Treg cells. Additionally, provided compositions convey improved half-life, stability and producibility over recombinant human IL2 formulations such as Proleukin®.